Rajesh Devraj retweeted
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Rajesh Devraj retweeted
We’re heading to @AASLDtweets #TLM26! We look forward to presenting translational data on our clinical candidate RTY-406, as a transformative therapy for hepatobiliary diseases, including PSC, PBC, and genetically associated chronic cholestasis.
Read more: bit.ly/3VTqqcx
Rajesh Devraj retweeted
Mike 3 things to consider 1) Revenue growth as modeled by sell side analysts and others is not equal to what is in the models of people who actually own stock and trade it, long buy side active funds 2) Pharma equity trades on an earnings multiple not a revenue multiple, margin expansion vs contraction can also explain “above or below” this line and 3) Terminal value assumptions matter - Organizations and management teams that have consistently demonstrated the ability to deliver organic R&D (Vertex) or BD (Abbvie) productivity get rewarded with a management premium/increased terminal value because the bet is they will do it again.
Rajesh Devraj retweeted
We Must Pace the Frontier: I’ve written a new essay on why the AI industry should slow down, with a three-part plan for doing so.
Anthropic is unilaterally committing to the first of these steps. We’ll provide third-party evaluators with permanent, employee-level access to our systems, so that they can verify adherence to our safety measures, report on incidents, and assess models’ alignment during training.
You can read the full post here: darioamodei.com/post/we-must…
Rajesh Devraj retweeted
The perfect man was delightfully imperfect. My story.
insidetennis.com/2026/08/rog…
Roger Federer's Hall of Fame speech mirrored his career: long (28 minutes), gave the illusion of perfect, but it was the cracks and the tears that made it raw, real, relatable.
Once again, so glad I chose him as my idol and my role model when I was a kid. youtube.com/watch?v=fQXTNAnY…
Rajesh Devraj retweeted
A re-up…for @SInow …”Roger Federer leaves a distinct, beautiful mark on tennis”
-
si.com/tennis/2022/09/15/rog…
Rajesh Devraj retweeted
Roger Federer's COMPLETE @TennisHalloFame Induction speech.
Stop what you are doing and enjoy this half an hour.
Rajesh Devraj retweeted
Roger Federer's Hall of Fame speech mirrored his career: long (28 minutes), gave the illusion of perfect, but it was the cracks and the tears that made it raw, real, relatable.
Once again, so glad I chose him as my idol and my role model when I was a kid. youtube.com/watch?v=fQXTNAnY…
As so eloquently penned by @BillSimons1 “the man who could not avoid beauty”. More please.
1
145
💯Effortless, sublime, poetry in motion.🙏🏼
With power, ease and beauty, Roger Federer navigated what we sensed but could not see. Championships end. Records fall. But what Federer gave us endures—the poetry, mystery and sublime beauty of the game.
Read: insidetennis.com/2026/08/rog… #Federer #HallOfFame
1
1
84
Rajesh Devraj retweeted
Time to re-think the way we approve drugs for mental health. Depression kills thousands, yet we wont do conditional approval of safe compounds that work but have high placebo effects. But we approve peptides with zero data.
Thanks @PharmaOnline and Rob Hughes to describe the potential of #PFMs a novel class of small molecule therapeutics that can restore/enhance membrane protein function.
What if small molecules could restore protein function instead of simply inhibiting it? Our CSO, Rob Hughes, Ph.D., discussed how positive functional modulators (#PFMs) can unlock new therapeutic opportunities in an interview with @PharmaOnline. Read here: bit.ly/43LVNXd
1
130
Rajesh Devraj retweeted
Patient-first, America-first: The Case For Global Collaboration
While the rise of Chinese biopharma in the past decade has been meteoric, I’m firmly in the camp that their engagement in the global ecosystem is good for the sector – its more opportunity than threat, great for patients, and is a healthy forcing function to raise the game for everyone
lifescivc.com/2026/06/patien…
Beyond our own borders let us not forget how quickly China can move on next-generation medicines once the target/mechanism is known.
Smart piece.
Getting big is a dangerous thing in drug discovery. Companies often lose what made them great. Lilly knows this! I've talked to them about this. But that doesn't make the transition easy.
1
170
Rajesh Devraj retweeted
American science is at risk.
Biopharma leaders with Trump’s ear: don’t let bootlicking become the methods section and sycophancy the new peer review.
Use your influence. Make the call. Save science.
biocentury.com/article/65961…
Rajesh Devraj retweeted
An appeal to @realDonaldTrump from those of us developing potentially life changing medicines. The next @US_FDA commissioner should have: deep regulatory experience, a track record of reform, and the ability to lead a scientific institution under political & competitive pressure without compromising speed or rigor nopatientleftbehind.org/fda-… Rick Pazdur is one exemplary candidate and the industry looks forward to supporting whoever is appointed. Thanks to @NPLB_org & @PeterKolchinsky for initiating - please sign & share.
If you are attending 2026 EASL Congress in Barcelona please visit us on May 29 where we will share data with our lead disease-modifying candidate for PSC.
Heading to #EASLCongress 2026? We look forward to connecting with the global liver community & sharing new preclinical data on RTY-406, our dual ABCB4/BSEP #PFMs candidate in development for #PSC & other hepatobiliary diseases. Learn more: bit.ly/3PCZXgn
101
Rajesh Devraj retweeted
For more than 70 years, British broadcaster and naturalist, Sir David Attenborough has brought nature to our screens.
At 100, he reflects on one unforgettable moment - coming face to face with mountain gorillas in Rwanda.
Here’s that encounter from 1979.
Great work by Rectify Pharma scientists to build a translational model that recapitulates bile-duct injury, inflammation, cholestasis and fibrotic phenotype seen in #PrimarySclerosingCholangitis (PSC).
Our new publication in Liver International Communications demonstrates how partial loss of ABCB4 function causes toxic bile composition and drives inflammation, fibrosis and liver injury. Read more: bit.ly/48ofBSW
191
Rajesh Devraj retweeted
Our new publication in Liver International Communications demonstrates how partial loss of ABCB4 function causes toxic bile composition and drives inflammation, fibrosis and liver injury. Read more: bit.ly/48ofBSW





















